Most people think precision is a feature. At PreciseDx, it’s the point. And with $11 million in fresh Series B-II capital lighting the path forward, they’re making it abundantly clear: in the business of cancer diagnostics, close enough is never good enough.
Born out of Mount Sinai’s deep bench of computational pathology, PreciseDx didn’t stumble into AI-driven digital diagnostics, they were engineering it before most med-tech startups figured out the difference between a slide and a scanner. What started as a spin-out in 2020 is now a full-force movement, armed with clinical validation across more than 3,000 breast cancer cases and a flagship product that delivers actionable intelligence in under 48 hours. Forget genomic testing that takes weeks and bleeds budgets, PreciseBreast™ gives oncologists exactly what they need, when they need it, at about 20% the cost.
Let’s pause and give it up for the minds behind the machine. Co-founders Carlos Cordon-Cardo, MD, PhD, Michael J. Donovan, MD, PhD, Gerardo Fernandez, MD, and Jack Zeineh, MD didn’t build this to chase headlines, they built it to save lives, and they’ve got the science (and the patents) to back it. New CEO Eric Converse and CFO Ed Sitar are now steering the commercial playbook, and they didn’t show up to babysit, they came to scale. With stints leading AMRA Medical AB, VirtualScopics, and diagnostics finance roles most VCs would sell their term sheets to understand, this duo isn’t guessing. They’re executing.
Let’s talk investors. Eventide Asset Management, Merck Global Health Innovation Fund, and Philips Ventures co-led this round, with Labcorp, Quest Diagnostics, and GenHenn Capital Venture backing the signal, not the noise. When your cap table looks like the boardroom at a JPMorgan health conference, you’re not pitching vision, you’re closing traction.
And the traction is real. CLIA-certified, NY State CLEP-validated, and a PLA CPT code already secured. Their tech? It’s called OncoIntelligence™, but it’s less hype and more backbreaker, analyzing nuclear shape, chromatin texture, tumor architecture, and spitting out recurrence risk like it’s reading the future off an H&E slide. No need for extra tissue, no dependence on HER2 or hormone receptor status, and no waiting around to find out what happens next.
This isn’t hype. It’s a hard pivot in how cancer diagnostics get done. 79% of breast cancer patients flagged as low-risk in comparative studies vs. 81% from Oncotype DX, and PreciseDx does it faster, cheaper, and with machine-learning fidelity that doesn’t blink.
They’re not stopping at breast cancer either. With international expansion on the table and exploratory proof-of-concept for Parkinson’s detection posting 99% sensitivity and specificity, the ceiling isn’t high, it’s irrelevant.
PreciseDx isn’t just diagnosing risk. They’re recalibrating how medicine measures it. Clinical truth in under 48 hours? That’s not innovation. That’s accountability.
